Trial results could lead to new age of treatment for pancreatic cancer

A precision cancer drug that’s designed to kill cancer cells that carry a fault in the BRCA genes could hold some advanced pancreatic cancers at bay for a short time after chemo, according to new clinical trial results.  Olaparib (Lynparza) delayed the progression of the disease by 7.4 months on average, compared with 3.8 months in those treated with a dummy drug (placebo), according to results reported at the American Society of Clinical Oncology (ASCO) Annual Meeting, and published in the New England Journal of Medicine. Longer term survival analysis is still needed to gauge the potential impact. But with pancreatic cancer among the most difficult